
Anthera Pharmaceuticals has announced that it is to terminate development of its investigational pancreatic enzyme replacement therapy (PERT) Sollpura after …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

